A Review of FDA Warning Letters and Notices of Violation Issued for Patient-Reported Outcomes Promotional Claims between 2006 and 2012
Authors:
- 1 June 2014
- journal article
- review article
- Published by Elsevier in Value in Health
- Vol. 17 (4) , 433-437
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Communicating and Promoting Comparative-Effectiveness Research FindingsNew England Journal of Medicine, 2013
- Communication About Results Of Comparative Effectiveness Studies: A Pharmaceutical Industry ViewHealth Affairs, 2012
- FDA Actions Against Health Economic Promotions, 2002–2011Value in Health, 2012
- Reasons for Rejection of Patient-Reported Outcome Label Claims: A Compilation Based on a Review of Patient-Reported Outcome Use among New Molecular Entities and Biologic License Applications, 2006–2010Value in Health, 2012
- A Review of Patient-Reported Outcome Labels in the United States: 2006 to 2010Value in Health, 2012
- FDA Actions against Misleading or Unsubstantiated Economic and Quality-of-Life Promotional Claims: An Analysis of Warning Letters and Notices of ViolationValue in Health, 2002
- The Regulation of Patient-Reported Outcome Claims: Need for a Flexible StandardValue in Health, 2002